INT34184

Context Info Confidence 0.65 First Reported 1987 Last Reported 2010 Negated 0 Speculated 0 Reported most in Abstract Documents 7 Total Number 7 Disease Relevance 2.68 Pain Relevance 4.21

cytosol (FGD1) signal transduction (FGD1) Golgi apparatus (FGD1) plasma membrane (FGD1) cytoskeleton (FGD1) nucleus (FGD1)

Anatomy Link Frequency Neuronal 1 cerebral cortex 1 FGD1 (Homo sapiens)

Pain Link Frequency Relevance Heat cva 28 100.00 Neurotransmitter 8 100.00 Glutamate 16 99.96 cerebral cortex 16 99.40 gABA 8 98.64 Angina 27 96.64 opiate 9 96.56 antagonist 4 95.92 narcan 4 95.48 Enkephalin 4 94.28

Disease Link Frequency Relevance Heat Pulmonary Embolism 25 100.00 Acute Coronary Syndrome 24 100.00 Syndrome 19 100.00 Aggression 15 99.50 Angina 30 96.64 Acne 6 87.48 Cv General 3 Under Development 2 62.88 Pain 11 50.00 Headache 3 50.00 Neuropathic Pain 2 50.00

Sentences Mentioned In

Key:

Protein

Mutation

Event

Anatomy

Negation

Speculation

Pain term

Disease term

Her aggressiveness worsened after starting AAS use and she increasingly frequently got into fights in order to find release for these feelings.

Localization (use) of AAS associated with aggression

1) Confidence 0.65 Published 2008 Journal Subst Abuse Treat Prev Policy Section Body Doc Link PMC2612649 Disease Relevance 0.28 Pain Relevance 0.16

CONCLUSION: Almotriptan 12.5 mg was efficacious in providing 2-hour pain free, 2-hour pain relief, SPF, and reducing rescue medication use irrespective of the presence of AAS at the time of treatment.

Localization (presence) of AAS

2) Confidence 0.35 Published 2009 Journal Headache Section Body Doc Link 19220503 Disease Relevance 0 Pain Relevance 0

In contrast, clinical scenarios where exclusion of either ACS and PE or ACS and AAS is necessary are fairly common.

Localization (exclusion) of AAS associated with acute coronary syndrome, syndrome and cva

3) Confidence 0.04 Published 2010 Journal Korean Circulation Journal Section Body Doc Link PMC3008823 Disease Relevance 2.40 Pain Relevance 0.86

The release of the putative neurotransmitter AAs glutamate (Glu), taurine (Tau), and glycine (Gly) were similarly increased by 50-150% with m-ENK in slices of CS, but not Cx.

Localization (release) of AAs associated with glutamate, neurotransmitter and cerebral cortex

4) Confidence 0.01 Published 1987 Journal J. Neurochem. Section Abstract Doc Link 3031217 Disease Relevance 0 Pain Relevance 0.80

The enhanced release of AAs by m-ENK was prevented by removal of extracellular Ca2+ or by preincubation with the opiate receptor antagonist naloxone.

Localization (release) of AAs associated with antagonist, narcan and opiate

5) Confidence 0.01 Published 1987 Journal J. Neurochem. Section Abstract Doc Link 3031217 Disease Relevance 0 Pain Relevance 0.86

Neuronal depolarization by potassium (5-55 mM) in the presence of Ca2+ did not affect the release of Tyr, whereas release of neurotransmitter AAs such as gamma-aminobutyric acid (GABA) were markedly increased.

Localization (release) of AAs in Neuronal associated with gaba and neurotransmitter

6) Confidence 0.01 Published 1987 Journal J. Neurochem. Section Abstract Doc Link 3031217 Disease Relevance 0 Pain Relevance 0.88

Amino acids (AAs) released from slices of CS and, for comparison, cerebral cortex (Cx) were measured by HPLC.

Localization (released) of AAs in cerebral cortex associated with cerebral cortex

7) Confidence 0.01 Published 1987 Journal J. Neurochem. Section Abstract Doc Link 3031217 Disease Relevance 0 Pain Relevance 0.65

General Comments

This test has worked.